BRPI0911228A2 - compostos e composições como inibidores de proteínas quinase - Google Patents

compostos e composições como inibidores de proteínas quinase

Info

Publication number
BRPI0911228A2
BRPI0911228A2 BRPI0911228A BRPI0911228A BRPI0911228A2 BR PI0911228 A2 BRPI0911228 A2 BR PI0911228A2 BR PI0911228 A BRPI0911228 A BR PI0911228A BR PI0911228 A BRPI0911228 A BR PI0911228A BR PI0911228 A2 BRPI0911228 A2 BR PI0911228A2
Authority
BR
Brazil
Prior art keywords
compositions
compounds
protein kinase
kinase inhibitors
inhibitors
Prior art date
Application number
BRPI0911228A
Other languages
English (en)
Inventor
Wu Baogen
Chen Bei
Huang Chen
Michellys Pierre-Yves
Jiang Tao
H Marsilje Thomas
Ngoc Nguyen Truc
Pei Wei
Zhu Xuefeng
Li Yuncheng
Gao Zhaobo
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of BRPI0911228A2 publication Critical patent/BRPI0911228A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
BRPI0911228A 2008-04-07 2009-04-03 compostos e composições como inibidores de proteínas quinase BRPI0911228A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4311108P 2008-04-07 2008-04-07
US11602308P 2008-11-19 2008-11-19
PCT/US2009/039383 WO2009126515A1 (en) 2008-04-07 2009-04-03 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0911228A2 true BRPI0911228A2 (pt) 2017-05-30

Family

ID=40756678

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911228A BRPI0911228A2 (pt) 2008-04-07 2009-04-03 compostos e composições como inibidores de proteínas quinase

Country Status (12)

Country Link
US (1) US8592432B2 (pt)
EP (1) EP2271630B1 (pt)
JP (1) JP5298187B2 (pt)
KR (1) KR101238585B1 (pt)
CN (1) CN102131788B (pt)
AU (1) AU2009233964B2 (pt)
BR (1) BRPI0911228A2 (pt)
CA (1) CA2720946C (pt)
EA (1) EA018282B1 (pt)
ES (1) ES2570127T3 (pt)
MX (1) MX2010010968A (pt)
WO (1) WO2009126515A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
KR101956261B1 (ko) 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
RU2535217C2 (ru) * 2009-02-06 2014-12-10 Ниппон Синяку Ко., Лтд. Производные аминопиразина и лекарственные средства
ES2559230T3 (es) 2009-05-08 2016-02-11 Astellas Pharma Inc. Compuesto de diamino-carboxamida heterocíclica
US8957065B2 (en) * 2010-06-23 2015-02-17 Hanmi Science Co., Ltd Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2012005299A1 (ja) * 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
CN103442568A (zh) * 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
EP2627179A4 (en) * 2010-10-14 2014-04-02 Ariad Pharma Inc METHODS OF INHIBITING CELL PROLIFERATION IN EGFR-INDUCED CANCERS
CN107056751A (zh) 2010-12-17 2017-08-18 诺华股份有限公司 一种alk抑制剂的结晶形式
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
RS54189B1 (en) * 2011-02-02 2015-12-31 Novartis Ag PROCEDURES FOR USING ALK INIBITORS
CN102757390B (zh) * 2011-04-27 2015-04-22 中国中化股份有限公司 一种制备2-甲氧基-4-肼基-5-氟嘧啶的方法
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
KR101379808B1 (ko) 2012-04-03 2014-04-24 울산대학교 산학협력단 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CA2890006C (en) 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
CN102977104A (zh) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 2,4-二氯-7-氢-吡咯并（2,3）嘧啶的合成
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
MX2016008362A (es) * 2013-12-23 2016-09-08 Novartis Ag Combinaciones farmaceuticas.
KR102455519B1 (ko) 2014-03-27 2022-10-14 얀센 파마슈티카 엔.브이. ＲＯＳ1 저해제로서의 치환된 4,5,6,7-테트라히드로피라졸로[1,5-ａ]피라진 유도체 및 5,6,7,8-테트라히드로-4Ｈ-피라졸로[1,5-ａ][1,4]디아제핀 유도체
US10053458B2 (en) 2014-06-17 2018-08-21 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN104803908A (zh) * 2015-03-26 2015-07-29 药源药物化学（上海）有限公司 2-异丙氧基-5-甲基-4-(4-哌啶基)苯胺二盐酸盐的水合物、其制备方法及用途
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
CN106699810A (zh) * 2015-11-17 2017-05-24 清华大学 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
CN107216319B (zh) * 2016-03-21 2021-10-08 中国科学院上海药物研究所 一种2，4-二氨基嘧啶类衍生物、其制备方法及用途
KR101937529B1 (ko) * 2016-07-26 2019-01-14 한국화학연구원 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN109715620B (zh) 2016-08-29 2022-05-06 密歇根大学董事会 作为alk抑制剂的氨基嘧啶
CN107793417B (zh) * 2016-09-05 2020-06-09 复旦大学 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
MA46620A (fr) * 2016-10-28 2021-05-26 Bristol Myers Squibb Co Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
CN108276410B (zh) * 2017-01-06 2021-12-10 首药控股(北京)股份有限公司 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途
KR102032418B1 (ko) * 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
US20190338244A1 (en) * 2017-11-30 2019-11-07 New York Medical College Multipotent adult stem cells: characterization and use
CN112645929B (zh) * 2019-10-11 2022-03-11 苏州泽璟生物制药股份有限公司 异丙磺酰基苯基嘧啶类化合物或其盐的多晶型物
WO2021073498A1 (zh) * 2019-10-17 2021-04-22 贝达药业股份有限公司 Egfr抑制剂、组合物及其制备方法
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用
WO2023128708A1 (ko) * 2021-12-30 2023-07-06 한국화학연구원 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN114805301B (zh) * 2022-04-29 2024-04-05 沈阳药科大学 2,4-二芳氨基嘧啶类化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196181T3 (es) * 1995-11-01 2003-12-16 Novartis Ag Derivados de purina y proceso para su preparacion.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4886511B2 (ja) * 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
ES2365223T3 (es) * 2003-08-07 2011-09-26 Rigel Pharmaceuticals, Inc. Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
CA2533320A1 (en) * 2003-08-15 2006-02-24 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CA2564199A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
JP2008520612A (ja) * 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
JP2008013527A (ja) * 2006-07-10 2008-01-24 Sankyo Co Ltd チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体
WO2008039359A2 (en) * 2006-09-25 2008-04-03 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
CN103641833A (zh) * 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
WO2009032694A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
MX2010002336A (es) * 2007-08-28 2010-03-25 Irm Llc Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa.

Also Published As

Publication number Publication date
EP2271630B1 (en) 2016-03-23
EA018282B1 (ru) 2013-06-28
ES2570127T3 (es) 2016-05-17
EA201001597A1 (ru) 2011-06-30
KR20110015414A (ko) 2011-02-15
MX2010010968A (es) 2010-10-26
KR101238585B1 (ko) 2013-02-28
JP2011516555A (ja) 2011-05-26
AU2009233964A1 (en) 2009-10-15
EP2271630A1 (en) 2011-01-12
US20110135668A1 (en) 2011-06-09
JP5298187B2 (ja) 2013-09-25
CA2720946C (en) 2013-05-28
WO2009126515A8 (en) 2010-10-21
CN102131788B (zh) 2014-03-19
US8592432B2 (en) 2013-11-26
WO2009126515A1 (en) 2009-10-15
AU2009233964B2 (en) 2012-06-07
CA2720946A1 (en) 2009-10-15
CN102131788A (zh) 2011-07-20

Similar Documents

Publication Publication Date Title
CY2019013I1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
BRPI0911228A2 (pt) compostos e composições como inibidores de proteínas quinase
CY2019009I1 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0914652A2 (pt) compostos e composições como inibidores de quinase
BRPI0719797A2 (pt) compostos e composições como inibidores de proteína cinase
BRPI0912668A2 (pt) composto e composições como inibidores de quinase
BRPI0906973A2 (pt) Compostos e composições como inibidores de cinase.
BR112012004448A2 (pt) "compostos e composições como inibidores de proteína cinase"
BRPI0910668A2 (pt) inibidores de proteína quinases
BRPI0908849A2 (pt) Composto e composições como c-kit e inibidores de pdgfr quinase
BRPI0811516A2 (pt) Compostos e composições como inibidores de c-kit e pdgfr cinase
BRPI0910979A2 (pt) compostos e composições como inibidores de quinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
BRPI0920239A2 (pt) compostos heterocíclicos como inibidores de proteínas quinases
BRPI0914545A2 (pt) compostos e composições como inibidores de quinase
BRPI0912475A8 (pt) compostos como inibidores de quinase
BRPI0811517A2 (pt) Compostos e composições como inibidores de c-kit e pdgfr cinase.
BRPI0716198A2 (pt) Pirrolo-isoquinolinas como inibidores de cinase
BRPI0910691A2 (pt) compostos e composições como inibidores de itpkb
BRPI0914936A2 (pt) naftiridininonas como inibidores de aurora quinase
LTPA2019004I1 (lt) Baltymų kinazės slopikliai
BRPI0907574A2 (pt) Inibidores de ligação de proteína quinase
DOP2009000099A (es) Compuestos y composiciones como inhibidores de proteina cinasa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]